It is made available under a CC-BY-NC-ND 4.0 International license .

SARS-CoV-2 serosurvey across multiple waves of the COVID-19 pandemic in New York City between 2020-2023

- 3
- 4
- 5 Juan Manuel Carreño^{1,2,*}, Abram L. Wagner^{3,*}, Brian Monahan^{1,2}, Daniel Floda⁴, Ana S Gonzalez-
- 6 Reiche⁴, Johnstone Tcheou^{1,2}, Ariel Raskin^{1,2}, Dominika Bielak^{1,2}, Gagandeep Singh^{1,2}, Sara
- 7 Morris^{1,2}, Miriam Fried^{1,2}, Temima Yellin^{1,2}, Leeba Sullivan^{1,2}, PARIS study group[#], Emilia Mia
- 8 Sordillo⁵, Aubree Gordon³, Harm van Bakel^{1,4,6}, Viviana Simon^{1,2,5,7,8,&}, Florian Krammer^{1,2,5,&}
- 9
- 10 ¹Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- ¹¹ ²Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine
- 12 at Mount Sinai, New York, NY, USA
- 13 ³Department of Epidemiology, School of Public Health, University of Michigan, 1415 Washington
- 14 Heights, Ann Arbor, MI 48109, US
- ⁴Department of Genetics and Genomic Sciences, ISMMS, New York, NY, USA.
- 16 ⁵Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at
- 17 Mount Sinai, New York, NY, USA
- 18 ⁶Icahn Genomics Institute, ISMMS, New York, NY, USA.
- 19 ⁷Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount
- 20 Sinai, New York, NY, USA
- 21 ⁸The Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai,
- 22 New York, NY, USA
- 23
- 24
- 25
- 26 *Contributed equally
- 27 & Corresponding authors: Emilia Mia Sordillo (Emilia.sordillo@mountsinai.org), Aubree Gordon
 28 (gordonal@umich.edu), Harm van Bakel (harm.vanbakel@mssm.edu), Viviana Simon
- 29 (viviana.simon@mssm.edu), Florian Krammer (florian.krammer@mssm.edu)
- 30 [#]PARIS study group: Fatima Amanat, Guha Asthagiri Arunkumar, Christina Capuano, Jordan
- 31 Ehrenhaus, Shelcie Fabre, Matthew M Hernandez, Kaijun Jiang, Brian Lerman, Meagan
- 32 McMahon, Daniel Stadlbauer, Jessica Tan, Catherine Teo, Kathryn Twyman,
- 33
- 34
- 35

It is made available under a CC-BY-NC-ND 4.0 International license .

36 ABSTRACT

37 Sero-monitoring provides context to the epidemiology of severe acute respiratory syndrome 38 coronavirus 2 (SARS-CoV-2) infections and changes in population immunity following vaccine 39 introduction. Here, we describe results of a cross-sectional hospital-based study of anti-spike 40 seroprevalence in New York City (NYC) from February 2020 to July 2022, and a follow-up period 41 from August 2023 to October 2023. Samples from 55,092 individuals, spanning five 42 epidemiological waves were analyzed. Prevalence ratios (PR) were obtained using Poisson 43 regression. Anti-spike antibody levels increased gradually over the first two waves, with a sharp 44 increase during the 3rd wave coinciding with SARS-CoV-2 vaccination in NYC resulting in 45 seroprevalence levels >90% by July 2022. Our data provide insights into the dynamic changes in 46 immunity occurring in a large and diverse metropolitan community faced with a new viral 47 pathogen and reflects the patterns of antibody responses as the pandemic transitions into an 48 endemic stage.

- 49
- 50

51 Keywords: COVID-19, SARS-CoV-2, spike, serosurvey, seroprevalence, antibody titers

It is made available under a CC-BY-NC-ND 4.0 International license .

52 Introduction

53

54 Coronavirus disease 2019 (COVID-19) has severely impacted human health worldwide. Within 55 the United States, New York City emerged as an early epicenter of infection and cases, with the 56 first reported case on February 29, 2020¹. However, public reporting of cases over time was 57 inconsistent due to limited testing capacity early in the pandemic¹. Moreover, testing was 58 differentially available to groups depending on their socioeconomic status², impacting 59 understanding of the course of the epidemic in different populations.

60

61 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-62 19, has rapidly evolved to increase its transmission potential and to evade immunity derived from 63 prior infection and vaccination, contributing to several waves of infections³. The emergence of 64 viral variants capable of overcoming pre-established immune responses is mainly attributed to 65 mutations in the spike surface glycoprotein. During the first wave of infections, the wild type 66 (WT) virus acquired the D614G mutation that increased virus infectivity and transmissibility^{4,5}. 67 These strains prevailed for several months until the second wave of infections caused by the 68 Alpha, Beta and Gamma variants occurred in different parts of the world. A 3rd wave of infections 69 was caused by the Delta variant which showed higher transmissibility and enhanced severe 70 disease. A significant reduction of viral neutralization by sera from convalescent or vaccinated 71 individuals was detected^{6,7}. In December 2021, the emergence of the Omicron BA.1 strain, which 72 carried over 30 spike protein mutations, resulted in a 4th wave of infections. Since then, distinct 73 Omicron sub-lineages have circulated worldwide, including BA.2, BA.5, BQ.1, BQ.1.1, BF.7, and 74 more recently XBB.1, XBB.1.5, BA.2.86, EG.5.1, JN.1, and derived variants.

75

Throughout the pandemic, monitoring the level of immunity in the population has been crucial for public health. Sero-monitoring has guided safety measures and vaccination policies worldwide to reduce viral infection, transmission, and severe disease⁸. Laboratories can measure binding antibodies to the spike (S) protein, which indicates past infection or vaccination, or antibodies to the nucleoprotein (NP), which indicates a past infection. The level of anti-SARS-CoV-2 antibodies and T cell responses correlate with an individual's capacity to combat the virus

It is made available under a CC-BY-NC-ND 4.0 International license .

and with protection against infection and disease^{9, 10}. Importantly, binding antibody levels
correlate with the number of prior exposures, and with the level of neutralizing antibodies^{11, 12}.
Hence, sero-surveillance for SARS-CoV-2 provides an estimate of the level of immunity in the
population and reflects the patterns of the pandemic. Moreover, existing case reporting systems
for COVID-19 are limited by changing testing availability and behaviors over time.

87

Here, we report the results of a prospective, hospital-based cross-sectional study of anti-S and anti-NP sero-monitoring from the beginning of February 2020 through July 2022, and follow-up measurements in August-October 2023. We describe the longitudinal seroprevalence in two different groups: a) an 'urgent care' group that was enriched for acute cases of COVID-19 early during the pandemic, and b) a 'routine care' group, resembling the general population, as previously described⁸. Stratification by zip code allowed us to study the geographical distribution of the seroprevalence and antibody titers in residents of NYC throughout the pandemic.

95

96 Methods

97 **Study participants and human samples.** Sample collection and testing started on February 9th, 98 2020 and ended on July 18th, 2022. Follow up testing started on August 28st 2023 and ended on 99 October 2nd 2023. Collection was performed on a weekly basis (n=608/week on average) and in a 100 blinded manner. Plasma was collected from ethylenediaminetetraacetic acid (EDTA)-treated 101 blood specimens that remained from standard-of-care testing at the Mount Sinai Hospital (MSH) 102 Blood Bank. Samples were sorted to collection week, visit location and practice including: 103 OB/GYN, labor and deliveries; oncology; surgery; cardiology; emergency department; and other 104 related hospital admissions. Up to 152 specimens at each location in a defined collection week 105 were randomly selected.

106

107 During sample aliquoting, specimens were captured into a coded database with randomly 108 assigned identifiers and verified patient categories. Additional specimens obtained from the same 109 patient within the same week were not considered for analysis. Samples collected 7 days apart or 110 more from the first specimen collected were considered as independent samples of the

It is made available under a CC-BY-NC-ND 4.0 International license .

111 population. Typically, 67-314 specimens were selected weekly from the 'routine care' group 112 (OB/GYN, labor and deliveries, oncology, surgery, and cardiology) and 67 to 314 samples from 113 the 'urgent care' group consisting of specimens from patient visits to the emergency department 114 and urgent care. Some individuals had a PCR test to diagnose SARS-CoV-2 infection. The 115 analyses of samples collected during the week ending on February 9th 2020 to July 5th 2020 were 116 reported previously⁸. We incorporate all samples with additional demographics data in the 117 current analysis in order to describe seroprevalence and antibody titers since the beginning of the 118 pandemic. We stratify our analyses by 'urgent care' vs 'routine care' groups to capture the fact 119 that access to non-urgent medical care was limited at the beginning of the pandemic¹³.

120

121 Specimen metadata included information on the individuals' age, sex, race, insurance status, and 122 whether they had received a COVID-19 vaccination prior to specimen collection. Due to the low 123 number of children in our study, we limit our main analysis to adults, and divided them into 18-124 44 years, 45-64 years, and 65+ years age groups. Information on race was based on self-reported 125 categories (e.g., Asian and Pacific Islander, African American, White, Other, and unknown). 126 Information on ethnicity (e.g., Hispanic or non-Hispanic) was not consistently available and, thus, 127 not included in our analysis. Medicaid and Medicare were collapsed into a public insurance 128 category. All data used in this study was anonymized and recoded through the use of an honest 129 broker following local regulations.

130

131 Epidemiological waves. We categorized samples by time into 5 epidemiological waves, that 132 correspond to successive peaks in COVID-19 incidence in NYC: Wave 1 (February 9th to August 133 30th, 2020; ancestral SARS-CoV-2 and D614G mutant circulating), Wave 2 (August 31st, 2020, to 134 June 20th, 2021; Iota (B.1.529) and Alpha (B.1.1.7) circulating), Wave 3 (June 21st to October 31st, 135 2021; Delta (B.1.617.2) circulating), Wave 4 (November 1st, 2021, to March 6th, 2022; Delta 136 (B.1.617.2) and Omicron BA.1 (B.1.1.529.1) circulating), and Wave 5 (March 7th to July 18th, 2022; 137 Omicron BA.2 (B.1.1.529.2) and Omicron BA.5 (B.1.1.529.5) circulating). Epidemiological waves 138 and circulating variants are depicted in Figures 1A and 1B respectively. The follow up period 139 (August 28st 2023 - October 2nd 2023), was not associated to a specific wave timeframe, and was

It is made available under a CC-BY-NC-ND 4.0 International license .

140 included to assess the maintenance of seroprevalence and durability of spike binding antibody141 titers.

142

143 Geographical maps. The neighborhood tabulation area (NTA) map created by the Department 144 of City Planning and sourced from NYC OpenData was used as the base geometry for our data 145 analyses. For each NTA, the average of the common logarithm of spike titer values was calculated 146 and plotted as a shaded map using the ggplot2 and sf packages in R. For plots showing 147 progression over time, slices were taken from each data range and plotted as separate facets.

148

149 Statistical analysis. We describe the distribution of results graphically and through proportions, 150 stratified by 'urgent care' vs 'routine care' groups. Visualizations of antibody prevalence and 151 titers were generated using Matplotlib (3.7.2), Seaborn (0.11.2), Pandas (1.5.3), Numpy (1.26.0), 152 and Scipy (1.11.3) packages within python 3.11.5. Geographical charts, and live data explorer 153 were generated using R version 4.3.2, with the packages sf (1.0.14), DT (0.31), zoo (1.8.12), Hmisc 154 (5.1.1), shiny (1.8.0), scico (1.5.0), ggpubr (0.6.0), bsplus (0.1.4), forcats (1.0.0), ggplot2 (3.4.4), 155 ggbreak (0.1.2), patchwork (1.1.3), lubridate (1.9.3), hrbrthemes (0.8.0), data.table (1.14.10), 156 shinyWidgets (0.8.0), RColorBrewer (1.1.3), shinydashboard (0.7.2), and shinycssloaders (1.0.0). 157

Based on *a priori* considerations, we include age, sex, race, and insurance status in our multivariable models: age representing differential humoral response to infection and increased risk of severe disease^{14, 15} and therefore a marker of potentially enhanced social distancing behaviors¹⁶, sex linked to health seeking behaviors¹⁷ as well as gynecological appointments, and race and insurance status measures of poverty, health seeking behaviors, and exposure to SARS-CoV-2 through a variety of mechanisms¹⁸.

164

Differences in seropositivity by demographic group over time were assessed through multivariable, Poisson regression models that included robust variance estimates¹⁹. These models output prevalence ratios (PR) and 95% confidence intervals (CI), which were interpreted relative to a reference group. These models estimated the direct effect of age, sex, race, and insurance

It is made available under a CC-BY-NC-ND 4.0 International license .

status on seropositivity. These models are initially stratified by epidemiological wave. To
estimate changes in seropositivity by demographic group across wave, we also specified a larger
model, where an interaction term was placed between wave and every demographic variable.
The p-value from this interaction term indicates if there has been a significant shift in differences
across wave, for a given demographic variable.

174

We conduct several sensitivity analyses. In a separate analysis, we also include vaccination, but limit the timing to data collected after January 11, 2021, when the vaccine started becoming available to certain age groups in the general population²⁰. And in a third set of models, we exclude individuals 65+ based on their ability to access Medicare. The regression models were implanted in SAS version 9.4 (SAS Institute, Cary, NC, USA). We used an alpha level of 0.05 to assess significance.

181

Ethical approval. The study protocol HS 20-00308 was reviewed by the Mount Sinai Health
System Institutional Review Board, Icahn School of Medicine at Mount Sinai, and it was exempt
from human research as defined by regulations of the Department of Health and Human Services
(45 CFR 46. 104).

186

187 **Data availability.** All data are available under ImmPort accession #xxx.

188

189 Results

190 Overall, there are 55,092 individuals sampled between February 9, 2020 and July 18, 2022: 21,075 191 from urgent care group and 34,017 from the routine care group. Of these 882 were children <18, 192 and 54,210 were adults. The demographic distribution among adults is shown in **Table 1**. In the 193 routine care groups, a plurality of individuals were in the 18-44 year age group (16,499, 49%), a 194 majority female (23,155, 69%), a plurality self-identified as White (14,971, 45%), and about half 195 had private insurance (16,386, 49%). The distribution of these variables for children is shown in 196 Supplementary Table 1. COVID-19 vaccination began in January 2021 in the general population 197 and varied across a number of groups, including race. Uptake was faster in Asian and Pacific

It is made available under a CC-BY-NC-ND 4.0 International license .

Islanders and White New Yorkers compared to African Americans (e.g., at wave 3, uptake in
these three groups was 63%, 55%, and 50%, respectively) (Supplementary Table 5).

200 We measured spike antibody prevalence and titers over five epidemiological waves based on 201 average case counts (7-day) of SARS-CoV-2 infections in New York City, reported by the NYC 202 Department of Health and Mental Hygiene (NYC DOHMH) (Figure 1A). Viral variant prevalence 203 through this period continuously changed, from the initial circulating of ancestral variants to the 204 appearance of variants of the Omicron lineage (Figure 1B). Overall, among adults in the routine 205 care group, spike protein seropositivity increased from an average of 13% in wave 1, to 36%, 76%, 206 88%, and 93% in the following four waves (Figure 1, C-D; Supplementary Table 2), consistent 207 with seroprevalence estimates reported by the NYC Department of Health and Mental Hygiene 208 (DOHMH)²¹. A sharp increase in antibody prevalence was detected during waves 2 and 3, starting 209 on February 2021. This increase was corresponded temporally with expanded availability of 210 SARS-CoV-2 vaccinations, the emergence of the Iota, Alpha, and Delta variants, and changes in 211 public health measures. Importantly, antibody prevalence was maintained during the follow up 212 period from August 28st 2023 to October 2nd 2023 (Figure 1, C-D). Vaccinated individuals showed 213 significantly higher antibody prevalence than non-vaccinated as early as January 2021, with the 214 largest differences just prior to and during wave 3 (Figure 2, G-H) owing to incomplete 215 vaccination in the earlier periods and unvaccinated individuals experiencing high infection rates 216 during wave 3. By wave 5, spike protein seropositivity was uniformly high (≥90% in all 217 categories). Similar trends were observed in populations stratified by gender and age, with no 218 significant differences among intra-group strata (Figure 2, A-D). Differences by race were 219 observed, for example, 14% of African Americans and 18% of those within the Other racial 220 category were seropositive in wave 1, versus 7% of Asians and Pacific Islanders (Figure 2, E-F).

221

The multivariable Poisson regression model of spike protein seropositivity reveals several trends within demographic group and across time (**Table 2**). At wave 1, seropositivity was higher in younger age groups compared to older (1.66 times higher in those 18-44 vs 65+, 95% CI: 1.41, 1.96). By wave 5, this had largely attenuated (interaction *p*-value <0.0001). Larger disparities by race were also observed at the beginning of the pandemic. Compared to White New Yorkers, Black

It is made available under a CC-BY-NC-ND 4.0 International license .

227 (prevalence ratios (PR): 1.24, 95% CI: 0.94, 1.63) and Other New Yorkers (PR: 1.64, 95% CI: 1.44, 228 1.88) had higher seropositivity, and Asians and Pacific Islanders had relatively low seropositivity 229 (PR: 0.67, 95% CI: 0.51, 0.87). During waves 3 and 4, some of these associations reversed, with 230 lower seropositivity in Black and Other groups compared to White New Yorkers. Around a 231 similar or earlier time (waves 2 and 3), vaccination coverage was relatively low among Black 232 compared to White New Yorkers (Supplementary Table 5). An analysis of spike protein 233 seropositivity across racial ethnic groups stratified by vaccination status reveals significant 234 differences among the unvaccinated (Supplementary Table 6), with seropositivity relatively high 235 in waves 1 through 2 and then relatively low in waves 3 and 4 in Black New Yorkers. However, 236 among the vaccinated, seropositivity remained equivalent across racial groups. Indeed, in the 237 models with vaccination status that cover periods once the vaccine had been rolled out 238 (Supplementary Table 3), this factor emerges as a significant contributor to seropositivity, with 239 a larger impact in wave 2, where seropositivity was 1.95 times higher among those vaccinated 240 compared to unvaccinated (95% CI: 1.87, 2.03), while it was only 1.04 times higher in wave 5 (95% 241 CI: 1.02, 1.07) (interaction *p*-value <0.0001).

242

243 Anti-spike antibody titers in seropositive individuals were induced at moderate to high levels 244 during the first waves of infections, with modest antibody decay over time (Figure 1, E-F; 245 **Supplementary Figure 1**). Amid the second wave, titers increased gradually reaching the highest 246 levels during wave 5. No significant differences were detected when titers were stratified by 247 gender, age or race (Figure 3, A-F). As expected, the introduction of vaccination during wave 2 248 resulted in increased antibody prevalence and titers at the time of sample collection, while 249 individuals without a record of vaccination displayed significantly lower antibody prevalence 250 through waves 2, 3 and 4 (Figures 2 and 3, G-H). These differences narrowed over time, likely 251 due to multiple infections in unvaccinated individuals. Moreover, differences in antibody 252 prevalence and titers in vaccinated vs non-vaccinated individuals were preserved when 253 stratification was based on sex, age, and race (Supplementary Figures 2-7).

It is made available under a CC-BY-NC-ND 4.0 International license .

255 For select weeks (July 6th-July 14th 2020, February 15th-March 1st 2021, June 1st - June 14th 2021, 256 August 16th – August 30th 2021, May 23rd – May 30th 2022, August 28th – Oct 2rd 2023) we also 257 measured seropositivity and titers for nucleoprotein (NP). Although initially in 2020 NP 258 seropositivity was similar to the spike seropositivity, this changed in 2021 as NP seropositivity 259 fell behind spike positivity by a relatively large margin (Figure 4). This was influenced not only 260 by vaccination (which only induces anti-spike antibodies) but also by waning of NP antibodies 261 over time and the low induction of NP antibodies during breakthrough infections. Our estimates 262 during mid 2021 (June 1st – June 14st, 57% (95% CI = 53.1–60.9) to late 2021 (August 16th – August 263 30th, 54% (95% CI = 50.5–57.5)) are higher than the reported nationwide NP seroprevalence 264 (December 2021 33.5% (95% CI = 33.1–34.0))²². These differences may be due to discrepancies in 265 the time points of antibody measurements. Antibodies induced or boosted during the Delta wave 266 may have waned over the subsequent months, due to the relatively fast decay rates of NP 267 antibodies induced by infection¹¹. Alternatively, differences in the sensitivity of the methods used 268 or higher COVID-19 incidence in NYC compared to nationwide levels²³ could have played a role. 269

270 To analyze the geographical distribution of antibody prevalence and titers through the five 271 boroughs of NYC (Manhattan, Brooklyn, Queens, The Bronx, and Staten Island), we used 272 neighborhood tabulation areas (NTAs) to build maps of the city divided into 216 NTAs (Figure 273 5). We detected higher antibody prevalence in areas located outside Manhattan during all waves 274 of infections, that were more evident during waves 1-3, when antibody prevalence was lower 275 (Figure 5, A-C). Importantly, seroprevalence reached high levels (above 80%) almost 276 homogenously throughout the five boroughs by wave 5 (Figure 5, E). Likewise, higher titers were 277 detected in boroughs other than Manhattan (Figure 6), with areas reaching the highest titers 278 located in Queens (Figure 6, E).

279

280 Discussion

281

Serosurveillance systems provide means to describe population patterns in infection and vaccination over time. Overall, in a hospital-based study in New York City, we previously described a sharp increase in anti-spike antibody prevalence early during 2020 due to SARS-CoV-

It is made available under a CC-BY-NC-ND 4.0 International license .

285 2 infections⁸. By May 2021, seroprevalence reached levels above 70% due to both infections, and 286 vaccination programs. Here we report on the continued sero-monitoring efforts to capture 287 antibody prevalence and titers over the course of the pandemic. We show that antibody 288 prevalence gradually increased over time, reaching levels above 90% by January 2022. 289 Seroprevalence and titers were maintained over time, with similar trends observed during a 290 follow up period in August-October, 2023, likely due to constant antigenic exposures by vaccine 291 boosters and breakthrough infections. Moreover, we analyzed the geographical distribution of 292 antibody prevalence and titers through the five boroughs of NYC. Finally, we analyzed NP titers 293 – indicative of immunity derived by infection – at discreet timepoints during the pandemic.

294

295 Our seroprevalence estimates for the most part overlap with estimates from the NYC DOHMH. 296 However, there are differences during the early phase of the pandemic and later during waves 4 297 and 5. Specifically, the NYC DOHMH reports a large proportion (>50%) of seropositive 298 individuals in wave 1 who were tested for SARS-CoV 2 by PCR. Individuals seeking testing were 299 probably more likely to be infected and potentially already antibody positive given the long 300 initial incubation time¹. This is similar to what we observed in the urgent care group that was 301 biased towards SARS-CoV-2 positives in the first wave. In more recent waves, seropositivity is 302 lower according to the NYC DOHMH than in our serosurveillance study. This could reflect 303 differences in the assays used or differences in the study populations.

304

305 The COVID-19 pandemic intensified racial and economic disparities in health²⁴. Our data 306 collected in the early waves, indicate that seropositivity was relatively high in adults self-307 identifying as Black and Others, pointing to higher infection rates in essential workers lacking 308 the possibility to socially distance or due socioeconomic constraints leading to more crowded 309 living conditions^{25, 26}. Our serosurveillance system revealed other sociodemographic trends by 310 age. These reflect epidemiological risk patterns and vaccination policies. For example, early in the 311 pandemic, seropositivity was greater in younger adults, in accordance with risk messaging 312 directed towards older adults. As vaccination became available and was prioritized for older 313 ages²⁷, seropositivity became relatively higher in older age groups.

It is made available under a CC-BY-NC-ND 4.0 International license .

314

315 The spike antibody response induced towards the emerging Omicron sub-lineages is mostly 316 cross-reactive with ancestral strains²⁸, hence the seroprevalence estimates presented here are 317 likely to be preserved towards the spike of Omicron sub-variants. Although the neutralization 318 capacity of sera from individuals exposed to ancestral SARS-CoV-2 antigens through infection or 319 vaccination is severely reduced against Omicron strains²⁹, non-neutralizing antibodies may 320 protect through alternative mechanisms mediated by Fc-dependent antibody effector functions³⁰ 321 and the presence of antibodies likely also indicates the presence of T-cell responses which largely 322 cross-react between different variants of concern ³¹. Dissecting the contribution of non-323 neutralizing cross-reactive antibodies upon exposure to emerging variants of the Omicron lineage 324 will be important to have a broader picture of an individual's immunity.

325

326 Our analysis has some limitations. Our catchment area was tied to individuals visiting the Mount 327 Sinai Health System, and we may have limited scope in generalizing outside the NYC 328 metropolitan area. Residual, de-identified samples are collected, which impedes following 329 individuals longitudinally. Representation of samples by different zones was limited, which 330 limited the geographical distribution analysis.

331

332 Conclusions

333 New York City was an early epicenter of the COVID-19 pandemic. Leveraging a hospital-based 334 serosurveillance system, we detect several patterns in line with the epidemiology of SARS-CoV-335 2 and the roll-out of the COVID-19 vaccines. Notably, by early 2022, virtually the entire 336 population had some evidence of COVID-19 seropositivity. Importantly our data clearly show 337 increasing overall seropositivity in the general population as SARS-CoV-2 vaccines became 338 available. The overall sustained high level of implied immunity in the total population also is 339 noteworthy. Finally, we believe our data set provides a great resource for additional modelling 340 studies and could help to predict immunity and seroprevalence scenarios during future 341 pandemics.

It is made available under a CC-BY-NC-ND 4.0 International license .

344 Acknowledgements

345 This effort was supported by the Serological Sciences Network (SeroNet) in part with Federal 346 funds from the National Cancer Institute, National Institutes of Health, under Contract No. 347 75N91019D00024, Task Order No. 75N91021F00001. The content of this publication does not 348 necessarily reflect the views or policies of the Department of Health and Human Services, nor 349 does mention of trade names, commercial products or organizations imply endorsement by the 350 U.S. Government. This work was also partially funded by the Centers of Excellence for Influenza 351 Research and Surveillance (CEIRS, contract # HHSN272201400008C), the Centers of Excellence 352 for Influenza Research and Response (CEIRR, contract # 75N93021C00014), by the Collaborative 353 Influenza Vaccine Innovation Centers (CIVICs contract # 75N93019C00051) and by institutional 354 funds.

355

356 **Conflict of interest**

357 The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-358 2 serological assays and NDV-based SARS-CoV-2 vaccines which list Florian Krammer as co-359 inventor. Dr. Simon is listed on the SARS-CoV-2 serological assays patent. Mount Sinai has spun 360 out a company, Kantaro, to market serological tests for SARSCoV-2. Dr. Krammer has consulted 361 for Merck, Segirus, CureVac and Pfizer in the past, and is currently consulting for Pfizer, 3rd Rock 362 Ventures, GSK and Avimex and he is a co-founder and scientific advisory board member of 363 CastleVax. The Krammer laboratory has been collaborating with Pfizer on animal models for 364 SARS-CoV-2.

365

366 Author contributions

F.K., V.S., H.v.B., A.G. and E.M.S. conceived and designed the study. H.v.B. wrote and
maintained the Institutional Review Board protocol. J.T., A.R., D.B., G.S., S.M., M.F., T.Y., and L.S.
performed the serological assays. J.M.C. and F.K. supervised serological assays. D.B., S.M, and
B.M. collected, organized and aliquoted plasma samples. G.S. produced and purified
recombinant proteins. J.M.C., J.T., B.M., and A.L.W. collected and analyzed the data. J.M.C., B.M.,
and D.F. generated figures. J.M.C. and A.L.W. wrote original manuscript draft. All authors edited
and approved the manuscript.

374 275	References	
376 377 378	1.	Thompson, C.N. <i>et al.</i> COVID-19 Outbreak - New York City, February 29-June 1, 2020. <i>MMWR Morb Mortal Wkly Rep</i> 69 , 1725-1729 (2020).
379 380 381 382	2.	Dalva-Baird, N.P., Alobuia, W.M., Bendavid, E. & Bhattacharya, J. Racial and ethnic inequities in the early distribution of U.S. COVID-19 testing sites and mortality. <i>Eur J Clin Invest</i> 51 , e13669 (2021).
383 384 385	3.	Carabelli, A.M. <i>et al.</i> SARS-CoV-2 variant biology: immune escape, transmission and fitness. <i>Nat Rev Microbiol</i> 21 , 162-177 (2023).
386 387 388	4.	Hou, Y.J. <i>et al.</i> SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. <i>Science</i> 370 , 1464-1468 (2020).
389 390 391	5.	Korber, B. <i>et al.</i> Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. <i>Cell</i> 182 , 812-827 e819 (2020).
392 393 394 395	6.	Carreno, J.M. <i>et al.</i> Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients. <i>EBioMedicine</i> 73 , 103626 (2021).
396 397 398	7.	Lucas, C. <i>et al.</i> Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity. <i>Nature</i> 600 , 523-529 (2021).
399 400 401	8.	Stadlbauer, D. <i>et al.</i> Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City. <i>Nature</i> 590 , 146-150 (2021).
402 403 404	9.	Khoury, D.S. <i>et al.</i> Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. <i>Nat Med</i> 27 , 1205-1211 (2021).
404 405 406 407	10.	Gilbert, P.B. <i>et al.</i> Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. <i>Science</i> 375 , 43-50 (2022).
408 409 410 411	11.	Carreno, J.M. <i>et al.</i> Longitudinal analysis of severe acute respiratory syndrome coronavirus 2 seroprevalence using multiple serology platforms. <i>iScience</i> 24 , 102937 (2021).
412 413 414 415	12.	Singh, G. <i>et al.</i> Binding and avidity signatures of polyclonal sera from individuals with different exposure histories to SARS-CoV-2 infection, vaccination, and Omicron breakthrough infections. <i>J Infect Dis</i> (2023).
416 417 418 419	13.	Schimmel, J., Vargas-Torres, C., Genes, N., Probst, M.A. & Manini, A.F. Changes in alcohol-related hospital visits during COVID-19 in New York City. <i>Addiction</i> 116 , 3525-3530 (2021).

420 421 422	14.	Zhang, J.J., Dong, X., Liu, G.H. & Gao, Y.D. Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality. <i>Clin Rev Allergy Immunol</i> 64 , 90-107 (2023).
422 423 424	15.	Aziz, H. <i>et al.</i> Antibody Response to SARS-CoV-2 in Relation to the Contributing Factors in COVID-19 Patients. <i>Viral Immunol</i> 35 , 142-149 (2022).
425 426 427	16.	Masters, N.B. <i>et al.</i> Social distancing in response to the novel coronavirus (COVID-19) in the United States. <i>PLoS One</i> 15 , e0239025 (2020).
428 429 430	17.	Currie, D. & Wiesenberg, S. Promoting women's health-seeking behavior: research and the empowerment of women. <i>Health Care Women Int</i> 24 , 880-899 (2003).
431 432 433	18.	De, P.K. Beyond race: Impacts of non-racial perceived discrimination on health access and outcomes in New York City. <i>PLoS One</i> 15 , e0239482 (2020).
434 435 436	19.	Spiegelman, D. & Hertzmark, E. Easy SAS calculations for risk or prevalence ratios and differences. <i>Am J Epidemiol</i> 162 , 199-200 (2005).
437 438 439 440	20.	Warren, C.M. <i>et al.</i> Assessment of Allergic and Anaphylactic Reactions to mRNA COVID-19 Vaccines With Confirmatory Testing in a US Regional Health System. <i>JAMA Netw Open</i> 4 , e2125524 (2021).
441 442 443	21.	Department, N.Y.C.H. COVID-19: Data. 2023 [cited 2023 May 25th]Available from: <u>https://www.nyc.gov/site/doh/covid/covid-19-data.page</u>
444 445 446 447	22.	Clarke, K.E.N. <i>et al.</i> Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies - United States, September 2021-February 2022. <i>MMWR Morb Mortal Wkly Rep</i> 71 , 606-608 (2022).
448 449 450 451	23.	Do, D.P. & Frank, R. Unequal burdens: assessing the determinants of elevated COVID- 19 case and death rates in New York City's racial/ethnic minority neighbourhoods. <i>J</i> <i>Epidemiol Community Health</i> (2020).
452 453 454	24.	Lopez, L., Hart, L.H. & Katz, M.H. Racial and Ethnic Health Disparities Related to COVID-19. <i>JAMA</i> 325 , 719-720 (2021).
455 456 457 458 459	25.	Honein, M.A. <i>et al.</i> Summary of Guidance for Public Health Strategies to Address High Levels of Community Transmission of SARS-CoV-2 and Related Deaths, December 2020. <i>MMWR Morb Mortal Wkly Rep</i> 69 , 1860-1867 (2020).
459 460 461 462	26.	Lieberman-Cribbin, W., Galanti, M. & Shaman, J. Socioeconomic Disparities in Severe Acute Respiratory Syndrome Coronavirus 2 Serological Testing and Positivity in New York City. <i>Open Forum Infect Dis</i> 8 , ofab534 (2021).
463 464 465	27.	A., C.D. Select New York state phase 1b groups are now eligible for COVID-19 vaccination. 2021 [cited 2023 August 25th]Available from:





Figure 1. SARS-CoV-2 spike binding antibody prevalence and titers in the Routine care and Urgent care groups at a
Mount Sinai Hospital in New York City (NYC). Average case counts (7-day) of SARS-CoV-2 infections in New York
City reported by the NYC Department of Health and Mental Hygiene (NYC DOHMH) (A). Main circulating SARSCoV-2 lineages based on data from the Pathogen Surveillance Program at Mount Sinai (B). Antibody prevalence (C, D)
and titers (E, F) in the Routine Care (left column, blue lines) and Urgent Care (right column, orange lines) groups,
measured between February 9th 2020 to July 18th 2022, and seroprevalence measured between August 21st 2023 to

It is made available under a CC-BY-NC-ND 4.0 International license .

October 2nd 2023. Charts are fitted with a bootstrapped confidence interval based on random resampling of results to

compute an estimate of the 95% confidence interval of the mean. In (B), lineages before the emergence of variants of

concern (VOCs) are shown in greyscale, while VOCs are shown in color. NYC DOHMH antibody prevalence data is

shown in C-D for reference, denoted with a dashed line. The date on which the first FDA-authorized SARS-CoV-2 vaccine became available in NYC is indicated by the vertical doted line and syringe. Alternating shaded areas in C-F

denote the five successive epidemiological waves of infection in NYC.

It is made available under a CC-BY-NC-ND 4.0 International license .



504 505 506

Figure 2. SARS-CoV-2 spike antibody prevalence stratified by demographic groups and vaccination status. Antibody 507 prevalence in the Routine Care (left column), and Urgent Care (right column) groups, measured between February 9th 508 2020 to July 18th 2022, and stratified by gender (A, B), age (C, D), race (E, F), and vaccination status at the time of sample 509 collection (G, H) is shown. Charts are fitted with a bootstrapped confidence interval based on random resampling of 510 results to compute an estimate of the 95% confidence interval of the mean. A, B. Gender stratification: males, females. 511 C, D. Categorical age levels: 18-44, 45-65, >65. Individuals <17 are not shown in this analysis. E, F. Race stratification: 512 White, African American, Asian and Pacific islander, Other, unknown. G,H. The date on which the first FDA-513 authorized SARS-CoV-2 vaccine became available in NYC is indicated by the vertical doted line and syringe. 514 Vaccination status was assessed at time of sample collection and does not reflect vaccination rates in NYC or within 515 our patient population.

516

It is made available under a CC-BY-NC-ND 4.0 International license .



Figure 3. SARS-CoV-2 spike antibody titers by demographic groups and vaccination status. SARS-CoV-2 spike antibody prevalence in the Routine Care (left column), and Urgent care (right column) groups measured between February 9th 2020 to July 18th 2022 stratified by gender (A, B), age (C, D), race (E, F), and vaccination status at the time of sample collection (G, H). Charts are fitted with a bootstrapped confidence interval based on random resampling of results to compute an estimate of the 95% confidence interval of the mean. A, B. Gender stratification: males, females. C, D. Categorical age levels: 18-44, 45-65, >65. Individuals <17 not shown in this analysis. E, F. Race stratification: White, African American, Asian and Pacific islander, Other, unknown. G,H. The date on which the first FDA-authorized 529 SARS-CoV-2 vaccine became available in NYC is indicated by the vertical doted line and syringe. Vaccination status 530 was assessed at time of sample collection and does not reflect vaccination rates in NYC or within our patient 531 population. 532

It is made available under a CC-BY-NC-ND 4.0 International license .



533

536 537 Figure 4. SARS-CoV-2 nucleoprotein (NP) and spike (S) antibody prevalence and titers over six sampling periods (2-538 week duration) through the course of the pandemic. NP and S antibody prevalence (A) and titers (B) in patients 539 540 541

attending a Mount Sinai Hospital in New York City are shown. Data stratified by vaccination status, assessed at the time of sample collection. Sampling time points: July 6th - July 20th, 2020; February 15th - March 1st, 2021; June 1st - June 14th, 2021; August 16th – August 30th, 2021; May 23rd - May 30th, 2022; Aug 28th – Oct 2nd, 2023. Antibody prevalence (%) 542 plus 95% confidence intervals are shown in A. Geometric mean of endpoint titers plus 95% confidence intervals are 543 shown in **B**. Limit of detection (LoD) is indicated by the horizontal dotted line. Statistically significant differences 544 between NP and S values are indicated as follows: ns, not significant; * <0.05, ** <0.01, *** <0.001 (Chi squared test for 545 antibody prevalence, and T test for Endpoint titer)"

546

547

It is made available under a CC-BY-NC-ND 4.0 International license .

549



550 551

552 Figure 5. Geographical distribution of SARS-CoV-2 spike antibody prevalence during five epidemiological waves of 553 COVID-19 in residents of New York City (NYC). SARS-CoV-2 spike IgG prevalence measured in patients from the five 554 boroughs of NYC (Manhattan, Brooklyn, Queens, The Bronx, and Staten Island) attending to a Mount Sinai Hospital 555 in NYC are shown. 5 epidemiological waves corresponding to successive peaks of COVID-19 incidence in NYC are 556 shown. A. Wave 1 (February 9th to August 30th, 2020). B. Wave 2 (August 31st, 2020, to June 20th, 2021). C. Wave 3 (June 557 21st to October 31st, 2021). D. Wave 4 (November 1st, 2021, to March 6th, 2022). E. Wave 5 (March 7th to July 18th, 2022). 558 Antibody prevalence is expressed as percent positivity within neighborhood tabulation areas. Areas with less than 10 559 specimens are shaded grey. Color gradient depicts percent positivity (0 to 100%).

- 560
- 561
- 562
- 563

It is made available under a CC-BY-NC-ND 4.0 International license .



566

Figure 6. Geographical distribution of SARS-CoV-2 spike antibody titers during five epidemiological waves of COVID-19 in residents of New York City (NYC). SARS-CoV-2 spike IgG titer measured in patients from the five boroughs of NYC (Manhattan, Brooklyn, Queens, The Bronx, and Staten Island) attending to a Mount Sinai Hospital in NYC are shown. 5 epidemiological waves corresponding to successive peaks of COVID-19 incidence are shown. A. Wave 1 (February 9th to August 30th, 2020). B. Wave 2 (August 31st, 2020, to June 20th, 2021). C. Wave 3 (June 21st to October 31st, 2021). D. Wave 4 (November 1st, 2021, to March 6th, 2022). E. Wave 5 (March 7th to July 18th, 2022). Antibody titer is expressed as log10 geometric mean titer. Areas with less than 10 specimens are shaded grey. Color gradient depicts range of antibody titers.

It is made available under a CC-BY-NC-ND 4.0 International license .



Supplementary Figure 1. Distribution of SARS-CoV-2 spike antibody titers during the serosurvey period. SARS-CoV-2 spike antibody titers in the Routine Care (left column), and Urgent care (right column) groups measured between February 9th 2020 to July 18th 2022. Weekly counts are presented per single column. Color gradient depicts the range of antibody titers.

It is made available under a CC-BY-NC-ND 4.0 International license .



Supplementary figure 2. SARS-CoV-2 spike antibody prevalence stratified by sex and vaccination status. Antibody prevalence in the Routine Care (top), and Urgent Care (bottom) groups, measured between February 9th 2020 to July 18th 2022, in vaccinated (left) and unvaccinated (right) inividuals. Charts are fitted with a bootstrapped confidence interval based on random resampling of results to compute an estimate of the 95% confidence interval of the mean. Vaccination status was assessed at time of sample collection and does not reflect vaccination rates in NYC or within our patient population.

It is made available under a CC-BY-NC-ND 4.0 International license .



Supplementary figure 3. SARS-CoV-2 spike antibody prevalence stratified by age and vaccination status. Antibody prevalence in the Routine Care (top), and Urgent Care (bottom) groups, measured between February 9th 2020 to July 18th 2022 in individuals with differen categorical age levels (18-44, 45-65, and >65 yeal old) in vaccinated (left) and unvaccinated (right) inividuals. Charts are fitted with a bootstrapped confidence interval based on random resampling of results to compute an estimate of the 95% confidence interval of the mean. Vaccination status was assessed at time of sample collection and does not reflect vaccination rates in NYC or within our patient population.



Supplementary figure 4. SARS-CoV-2 spike antibody prevalence stratified by race and vaccination status. Antibody prevalence in the Routine Care (top), and Urgent Care (bottom) groups, measured between February 9th 2020 to July 18th 2022 in individuals of different racial categories (White, African American, Asian and Pacific islander, Other, unknown) in vaccinated (left) and unvaccinated (right) individuals. Charts are fitted with a bootstrapped confidence interval based on random resampling of results to compute an estimate of the 95% confidence interval of the mean. Vaccination status was assessed at time of sample collection and does not reflect vaccination rates in NYC or within our patient population.

It is made available under a CC-BY-NC-ND 4.0 International license .

Supplementary figure 5. SARS-CoV-2 anti-spike antibody titers stratified by sex and vaccination status. Antibody prevalence in the Routine Care (top), and Urgent Care (bottom) groups, measured between February 9th 2020 to July 18th 2022, in vaccinated (left) and unvaccinated (right) inividuals. Charts are fitted with a bootstrapped confidence interval based on random resampling of results to compute an estimate of the 95% confidence interval of the mean. Vaccination status was assessed at time of sample collection and does not reflect vaccination rates in NYC or within our patient population.

It is made available under a CC-BY-NC-ND 4.0 International license .

687

Supplementary figure 6. SARS-CoV-2 anti-spike antibody titers stratified by age and vaccination status. Antibody prevalence in the Routine Care (top), and Urgent Care (bottom) groups, measured between February 9th 2020 to July 18th 2022 in individuals with differen categorical age levels (18-44, 45-65, and >65 yeal old) in vaccinated (left) and unvaccinated (right) inividuals. Charts are fitted with a bootstrapped confidence interval based on random resampling of results to compute an estimate of the 95% confidence interval of the mean. Vaccination status was assessed at time of sample collection and does not reflect vaccination rates in NYC or within our patient population.

Supplementary figure 7. SARS-CoV-2 anti-spike antibody titers stratified by race and vaccination status. Antibody prevalence in the Routine Care (top), and Urgent Care (bottom) groups, measured between February 9th 2020 to July 18th 2022 in individuals of different racial categories (White, African American, Asian and Pacific islander, Other, unknown) in vaccinated (left) and unvaccinated (right) individuals. Charts are fitted with a bootstrapped confidence interval based on random resampling of results to compute an estimate of the 95% confidence interval of the mean. Vaccination status was assessed at time of sample collection and does not reflect vaccination rates in NYC or within our patient population.